"They say that common baking soda will cure the disease," he continued, "that they have cured it with it, that they have no deaths up there at all; they use common baking soda, which cures the disease." Production
Sodium bicarbonate is produced industrially from sodium carbonate:
Na2CO3 +  CO2  +  H2O  →  2 NaHCO3It is produced on the scale of about 100,000 tonnes/year (as of 2001) with a worldwide production capacity of 2.4 million tonnes per year (as of 2002). Commercial quantities of baking soda are also produced by a similar method: soda ash, mined in the form of the ore trona, is dissolved in water and treated with carbon dioxide. Sodium bicarbonate precipitates as a solid from this solution.Regarding the Solvay process, sodium bicarbonate is an intermediate in the reaction of sodium chloride, ammonia, and carbon dioxide. The product however shows low purity (75pc). NaCl + CO2 + NH3 + H2O → NaHCO3 + NH4ClAlthough of no practical value, NaHCO3 may be obtained by the reaction of carbon dioxide with an aqueous solution of sodium hydroxide:
CO2 + NaOH → NaHCO3

Mining
Naturally occurring deposits of nahcolite (NaHCO3) are found in the Eocene-age (55.8–33.9 Mya) Green River Formation, Piceance Basin in Colorado. Nahcolite was deposited as beds during periods of high evaporation in the basin.
Society and culture
Economics
In September 2021, Merck signed a voluntary licensing agreement with the Medicines Patent Pool (MPP) that allows MPP to sublicense molnupiravir and supply the COVID-19 oral medication to 105 low- and middle-income countries. The cost of the U.S. governments initial purchase was about $712 per course of treatment; treatment with generics in developing countries can cost as little as $20. Legal status
On 11 October 2021, Merck submitted an EUA application to the FDA, and on 30 November 2021, the FDAs Antimicrobial Drugs Advisory Committee (AMDAC) at the Center for Drug Evaluation and Research met to discuss the application. The committee narrowly voted, 13 for and 10 opposed, to recommend authorization for adults with mild to moderate illness who are at high risk of developing severe COVID-19. Concerns were expressed over the drugs low effectiveness in preventing death, which in the final trial was only 30%, as well as the increased mutation rate the drug causes, which could theoretically worsen the pandemic by driving the evolution of more dangerous variants.